Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study

Authors: Catherine Anscombe, Samantha Lissauer, Herbert Thole, Jamie Rylance, Dingase Dula, Mavis Menyere, Belson Kutambe, Charlotte van der Veer, Tamara Phiri, Ndaziona P. Banda, Kwazizira S. Mndolo, Kelvin Mponda, Chimota Phiri, Jane Mallewa, Mulinda Nyirenda, Grace Katha, Henry Mwandumba, Stephen B. Gordon, Kondwani C. Jambo, Jennifer Cornick, Nicholas Feasey, Kayla G. Barnes, Ben Morton, Philip M. Ashton, Blantyre COVID-19 Consortium

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Compared to the abundance of clinical and genomic information available on patients hospitalised with COVID-19 disease from high-income countries, there is a paucity of data from low-income countries. Our aim was to explore the relationship between viral lineage and patient outcome.

Methods

We enrolled a prospective observational cohort of adult patients hospitalised with PCR-confirmed COVID-19 disease between July 2020 and March 2022 from Blantyre, Malawi, covering four waves of SARS-CoV-2 infections. Clinical and diagnostic data were collected using an adapted ISARIC clinical characterization protocol for COVID-19. SARS-CoV-2 isolates were sequenced using the MinION™ in Blantyre.

Results

We enrolled 314 patients, good quality sequencing data was available for 55 patients. The sequencing data showed that 8 of 11 participants recruited in wave one had B.1 infections, 6/6 in wave two had Beta, 25/26 in wave three had Delta and 11/12 in wave four had Omicron. Patients infected during the Delta and Omicron waves reported fewer underlying chronic conditions and a shorter time to presentation. Significantly fewer patients required oxygen (22.7% [17/75] vs. 58.6% [140/239], p < 0.001) and steroids (38.7% [29/75] vs. 70.3% [167/239], p < 0.001) in the Omicron wave compared with the other waves. Multivariable logistic-regression demonstrated a trend toward increased mortality in the Delta wave (OR 4.99 [95% CI 1.0–25.0 p = 0.05) compared to the first wave of infection.

Conclusions

Our data show that each wave of patients hospitalised with SARS-CoV-2 was infected with a distinct viral variant. The clinical data suggests that patients with severe COVID-19 disease were more likely to die during the Delta wave.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brito AF, Semenova E, Dudas G, et al. Global disparities in SARS-CoV-2 genomic surveillance. medRxiv 2021; :2021.08.21.21262393. Brito AF, Semenova E, Dudas G, et al. Global disparities in SARS-CoV-2 genomic surveillance. medRxiv 2021; :2021.08.21.21262393.
2.
go back to reference Aborode AT, Hasan MM, Jain S, et al. Impact of poor disease surveillance system on COVID-19 response in africa: time to rethink and rebuilt. Clin Epidemiol Global Health. 2021;12: 100841.CrossRef Aborode AT, Hasan MM, Jain S, et al. Impact of poor disease surveillance system on COVID-19 response in africa: time to rethink and rebuilt. Clin Epidemiol Global Health. 2021;12: 100841.CrossRef
3.
go back to reference Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399:437–46.CrossRef Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399:437–46.CrossRef
6.
go back to reference Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.CrossRef Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.CrossRef
7.
go back to reference Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.CrossRef Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.CrossRef
11.
go back to reference Nyasulu JCY, Munthali RJ, Nyondo-Mipando AL, et al. COVID-19 pandemic in Malawi: did public sociopolitical events gatherings contribute to its first-wave local transmission? Int J Infect Dis. 2021;106:269–75.CrossRef Nyasulu JCY, Munthali RJ, Nyondo-Mipando AL, et al. COVID-19 pandemic in Malawi: did public sociopolitical events gatherings contribute to its first-wave local transmission? Int J Infect Dis. 2021;106:269–75.CrossRef
12.
go back to reference Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. Nat Commun. 2021;12:3554.CrossRef Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. Nat Commun. 2021;12:3554.CrossRef
13.
go back to reference Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35–42.CrossRef Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35–42.CrossRef
14.
go back to reference Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. Lancet Infect Dis. 2021;21:1351.CrossRef Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. Lancet Infect Dis. 2021;21:1351.CrossRef
15.
go back to reference Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. Lancet Infect Dis. 2021;21:1629–30.CrossRef Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. Lancet Infect Dis. 2021;21:1629–30.CrossRef
16.
go back to reference Hussey H, Davies M-A, Heekes A, et al. Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections—a survival analysis. Int J Infect Dis. 2022;118:150–4.CrossRef Hussey H, Davies M-A, Heekes A, et al. Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections—a survival analysis. Int J Infect Dis. 2022;118:150–4.CrossRef
19.
go back to reference Banda NP, Hara W, Cocker D, et al. First case report of a successfully managed severe COVID-19 infection in Malawi. Malawi Med J. 2020;32:226–8. Banda NP, Hara W, Cocker D, et al. First case report of a successfully managed severe COVID-19 infection in Malawi. Malawi Med J. 2020;32:226–8.
20.
go back to reference Simulundu E, Mupeta F, Chanda-Kapata P, et al. First COVID-19 case in Zambia—comparative phylogenomic analyses of SARS-CoV-2 detected in African countries. Int J Infect Dis. 2021;102:455–9.CrossRef Simulundu E, Mupeta F, Chanda-Kapata P, et al. First COVID-19 case in Zambia—comparative phylogenomic analyses of SARS-CoV-2 detected in African countries. Int J Infect Dis. 2021;102:455–9.CrossRef
22.
go back to reference O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021; :veab064. O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021; :veab064.
25.
go back to reference Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327:583–4.CrossRef Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327:583–4.CrossRef
26.
go back to reference Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19:3.CrossRef Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19:3.CrossRef
27.
go back to reference Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 2022;116:38–42.CrossRef Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 2022;116:38–42.CrossRef
30.
go back to reference Weigang S, Fuchs J, Zimmer G, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. 2021;12:6405.CrossRef Weigang S, Fuchs J, Zimmer G, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. 2021;12:6405.CrossRef
32.
go back to reference Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30:154-162.e5.CrossRef Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30:154-162.e5.CrossRef
34.
go back to reference Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med. 2021;19:303.CrossRef Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med. 2021;19:303.CrossRef
Metadata
Title
A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
Authors
Catherine Anscombe
Samantha Lissauer
Herbert Thole
Jamie Rylance
Dingase Dula
Mavis Menyere
Belson Kutambe
Charlotte van der Veer
Tamara Phiri
Ndaziona P. Banda
Kwazizira S. Mndolo
Kelvin Mponda
Chimota Phiri
Jane Mallewa
Mulinda Nyirenda
Grace Katha
Henry Mwandumba
Stephen B. Gordon
Kondwani C. Jambo
Jennifer Cornick
Nicholas Feasey
Kayla G. Barnes
Ben Morton
Philip M. Ashton
Blantyre COVID-19 Consortium
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07941-y

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine